article · Journal of Bioscience and Applied Research/Journal of Bioscience and Applied Research
Heart failure has been considered in the last few years as a major factor in global mortality. Heart failure is known as the reduced ability of the heart muscle to fill or/and to pump adequate blood. Finding a diagnostic biomarker is necessary to help in the early diagnosis of heart diseases. MicroRNAs are new biomarkers that have been used for early diagnosis of various diseases. The work aims to study miR-34a in patients with heart failure and assess its diagnosing role. In this work, a total of (120) subjects were divided into three groups as the following, the control group (n=20) of healthy individuals, group II (n=50) the patients with heart failure post myocardial infarction & group III (n=50) the patients with heart failure without myocardial infarction history. microRNA-34a expression showed high expression and significant elevation (P- value < 0.5) in group-II (31.67±11.8 fold) and group-III (27.31±12.4fold) compared with group-I (1.47±0.7 fold). Our results showed that microRNA-34a plays a critical role in patients with heart failure disease and can be used as a biomarker for the diagnosis of early stages of heart failure disease.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/jbaar.2023.331876
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.